New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 19, 2014
07:20 EDTICPTIntercept data should be positive catalyst for shares, says Oppenheimer
Oppenheimer predicts that top-line data for Intercept's Phase 2 FLINT study in NASH, expected to be released in July, will be a positive catalyst for the stock. The firm thinks that the risk/reward ratio for the stock heading into the data release should be attractive as long as expectations remain modest. It keeps a $499 price target and Outperform rating on the stock.
News For ICPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 18, 2014
06:33 EDTICPTIntercept coverage resumed with a Buy at Sterne Agee
Subscribe for More Information
December 15, 2014
08:58 EDTICPTIntercept reinstated with a Buy at BofA/Merrill
Subscribe for More Information
December 11, 2014
08:57 EDTICPTLeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information
December 5, 2014
06:06 EDTICPTIntercept announces publication of meta-analysis from Global PBC Study Group
Subscribe for More Information
December 4, 2014
10:08 EDTICPTOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:22 EDTICPTIntercept endpoint for NASH trial achievable, says Summer Street
Subscribe for More Information
06:16 EDTICPTIntercept initiated with an Outperform at RW Baird
Target $258.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use